These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 24287290)

  • 1. The cell cycle arrest and the anti-invasive effects of nitrogen-containing bisphosphonates are not mediated by DBF4 in breast cancer cells.
    Mansouri M; Mirzaei SA; Lage H; Mousavi SS; Elahian F
    Biochimie; 2014 Apr; 99():71-6. PubMed ID: 24287290
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of the mevalonate pathway and activation of p38 MAP kinase are independently regulated by nitrogen-containing bisphosphonates in breast cancer cells.
    Merrell MA; Wakchoure S; Lehenkari PP; Harris KW; Selander KS
    Eur J Pharmacol; 2007 Sep; 570(1-3):27-37. PubMed ID: 17640631
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of secondary targets of N-containing bisphosphonates in mammalian cells via parallel competition analysis of the barcoded yeast deletion collection.
    Bivi N; Romanello M; Harrison R; Clarke I; Hoyle DC; Moro L; Ortolani F; Bonetti A; Quadrifoglio F; Tell G; Delneri D
    Genome Biol; 2009; 10(9):R93. PubMed ID: 19744312
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bisphosphonates directly regulate cell proliferation, differentiation, and gene expression in human osteoblasts.
    Reinholz GG; Getz B; Pederson L; Sanders ES; Subramaniam M; Ingle JN; Spelsberg TC
    Cancer Res; 2000 Nov; 60(21):6001-7. PubMed ID: 11085520
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential effects of bisphosphonates on breast cancer cell lines.
    Verdijk R; Franke HR; Wolbers F; Vermes I
    Cancer Lett; 2007 Feb; 246(1-2):308-12. PubMed ID: 16621245
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibitory effects of a new bisphosphonate, minodronate, on proliferation and invasion of a variety of malignant bone tumor cells.
    Kubo T; Shimose S; Matsuo T; Tanaka K; Yasunaga Y; Sakai A; Ochi M
    J Orthop Res; 2006 Jun; 24(6):1138-44. PubMed ID: 16705696
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vivo phosphoantigen levels in bisphosphonate-treated human breast tumors trigger Vγ9Vδ2 T-cell antitumor cytotoxicity through ICAM-1 engagement.
    Benzaïd I; Mönkkönen H; Bonnelye E; Mönkkönen J; Clézardin P
    Clin Cancer Res; 2012 Nov; 18(22):6249-59. PubMed ID: 23032740
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nitrogen-containing bisphosphonates can inhibit angiogenesis in vivo without the involvement of farnesyl pyrophosphate synthase.
    Stresing V; Fournier PG; Bellahcène A; Benzaïd I; Mönkkönen H; Colombel M; Ebetino FH; Castronovo V; Clézardin P
    Bone; 2011 Feb; 48(2):259-66. PubMed ID: 20920623
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Zoledronate inhibits the proliferation, adhesion and migration of vascular smooth muscle cells.
    Wu L; Zhu L; Shi WH; Zhang J; Ma D; Yu B
    Eur J Pharmacol; 2009 Jan; 602(1):124-31. PubMed ID: 19000670
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Probenecid as a sensitizer of bisphosphonate-mediated effects in breast cancer cells.
    Ebert R; Meissner-Weigl J; Zeck S; Määttä J; Auriola S; Coimbra de Sousa S; Mentrup B; Graser S; Rachner TD; Hofbauer LC; Jakob F
    Mol Cancer; 2014 Dec; 13():265. PubMed ID: 25496233
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Platinum-zoledronate complex blocks gastric cancer cell proliferation by inducing cell cycle arrest and apoptosis.
    Yang H; Qiu L; Zhang L; Lv G; Li K; Yu H; Xie M; Lin J
    Tumour Biol; 2016 Aug; 37(8):10981-92. PubMed ID: 26891667
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bisphosphonates modulate vital functions of human osteoblasts and affect their interactions with breast cancer cells.
    Kaiser T; Teufel I; Geiger K; Vater Y; Aicher WK; Klein G; Fehm T
    Breast Cancer Res Treat; 2013 Jul; 140(1):35-48. PubMed ID: 23807419
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alendronate inhibits proliferation and invasion of human epidermoid carcinoma cells in vitro.
    Muller S; Migianu E; Lecouvey M; Kraemer M; Oudar O
    Anticancer Res; 2005; 25(4):2655-60. PubMed ID: 16080508
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro toxicity of bisphosphonates on human neuroblastoma cell lines.
    Vorotnjak M; Boos J; Lanvers-Kaminsky C
    Anticancer Drugs; 2004 Sep; 15(8):795-802. PubMed ID: 15494642
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Zoledronate inhibits proliferation and induces apoptosis of imatinib-resistant chronic myeloid leukaemia cells.
    Chuah C; Barnes DJ; Kwok M; Corbin A; Deininger MW; Druker BJ; Melo JV
    Leukemia; 2005 Nov; 19(11):1896-904. PubMed ID: 16167056
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High levels of Cdc7 and Dbf4 proteins can arrest cell-cycle progression.
    Guo B; Romero J; Kim BJ; Lee H
    Eur J Cell Biol; 2005 Dec; 84(12):927-38. PubMed ID: 16325502
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nitrogen containing bisphosphonates induce apoptosis and inhibit the mevalonate pathway, impairing Ras membrane localization in prostate cancer cells.
    Oades GM; Senaratne SG; Clarke IA; Kirby RS; Colston KW
    J Urol; 2003 Jul; 170(1):246-52. PubMed ID: 12796698
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibitors of the mevalonate pathway as potential therapeutic agents in multiple myeloma.
    Baulch-Brown C; Molloy TJ; Yeh SL; Ma D; Spencer A
    Leuk Res; 2007 Mar; 31(3):341-52. PubMed ID: 16996129
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bisphosphonates inhibit the growth of mesothelioma cells in vitro and in vivo.
    Wakchoure S; Merrell MA; Aldrich W; Millender-Swain T; Harris KW; Triozzi P; Selander KS
    Clin Cancer Res; 2006 May; 12(9):2862-8. PubMed ID: 16675582
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bisphosphonates affect migration ability and cell viability of HUVEC, fibroblasts and osteoblasts in vitro.
    Walter C; Pabst A; Ziebart T; Klein M; Al-Nawas B
    Oral Dis; 2011 Mar; 17(2):194-9. PubMed ID: 20796232
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.